- Home
- SNGX vs CHNR Comparison
SNGX vs CHNR Comparison
Compare SNGX & CHNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- CHNR
- Stock Information
- Founded
- SNGX 1987
- CHNR N/A
- Country
- SNGX United States
- CHNR Hong Kong
- Employees
- SNGX N/A
- CHNR N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- CHNR Precious Metals
- Sector
- SNGX Health Care
- CHNR Basic Materials
- Exchange
- SNGX Nasdaq
- CHNR Nasdaq
- Market Cap
- SNGX 6.5M
- CHNR 5.2M
- IPO Year
- SNGX 1987
- CHNR 1995
- Fundamental
- Price
- SNGX $1.86
- CHNR $0.56
- Analyst Decision
- SNGX
- CHNR
- Analyst Count
- SNGX 0
- CHNR 0
- Target Price
- SNGX N/A
- CHNR N/A
- AVG Volume (30 Days)
- SNGX 26.0K
- CHNR 50.3K
- Earning Date
- SNGX 05-09-2025
- CHNR 05-15-2025
- Dividend Yield
- SNGX N/A
- CHNR N/A
- EPS Growth
- SNGX N/A
- CHNR N/A
- EPS
- SNGX N/A
- CHNR N/A
- Revenue
- SNGX $2,342.00
- CHNR N/A
- Revenue This Year
- SNGX N/A
- CHNR N/A
- Revenue Next Year
- SNGX N/A
- CHNR N/A
- P/E Ratio
- SNGX N/A
- CHNR N/A
- Revenue Growth
- SNGX N/A
- CHNR N/A
- 52 Week Low
- SNGX $1.68
- CHNR $0.45
- 52 Week High
- SNGX $14.83
- CHNR $1.13
- Technical
- Relative Strength Index (RSI)
- SNGX 38.46
- CHNR 52.58
- Support Level
- SNGX $1.83
- CHNR $0.51
- Resistance Level
- SNGX $2.00
- CHNR $0.66
- Average True Range (ATR)
- SNGX 0.10
- CHNR 0.05
- MACD
- SNGX -0.00
- CHNR 0.00
- Stochastic Oscillator
- SNGX 11.11
- CHNR 35.87
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About CHNR China Natural Resources Inc.
China Natural Resources Inc is an investment holding company. It principally engaged in the exploration and mining and wastewater treatment businesses in the People's Republic of China. The company has two operating segments: (i) Wastewater treatment segment, which consists of sales of assembled equipment, provision of construction service, and participation in PPP projects as an operator (ii) Exploration and mining segment, which consists of the exploration of lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and the trading of copper ores products. It earns the majority of its revenue from the Wastewater treatment segment.